BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhan H, Meng Y, Fan Z, Yang J, Li Y, Liu S, Gao C. The characteristics of serum lipid spectrum in PanNENs and its correlation with clinicopathological features and prognosis.. [DOI: 10.21203/rs.3.rs-2252618/v1] [Reference Citation Analysis]
2 Lysanyuk MV, Romashchenko PN, Maistrenko NA. Modern opportunities and problematic aspects of diagnostics and treatment of patients with neuroendocrine tumors. Perm Medical Journal 2022;39:58-68. [DOI: 10.17816/pmj39558-68] [Reference Citation Analysis]
3 Fu M, Yu L, Yang L, Chen Y, Chen X, Hu Q, Sun H. Predictive value of the preoperative prognostic nutritional index for postoperative progression in patients with pancreatic neuroendocrine neoplasms. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.945833] [Reference Citation Analysis]
4 Ruggeri RM, Benevento E, De Cicco F, Fazzalari B, Guadagno E, Hasballa I, Tarsitano MG, Isidori AM, Colao A, Faggiano A; NIKE Group. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. J Endocrinol Invest 2022. [PMID: 36038743 DOI: 10.1007/s40618-022-01905-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Angelico R, Siragusa L, Pathirannehalage Don CB, Sensi B, Billeci F, Vattermoli L, Padial B, Palmieri G, Anselmo A, Coppola A, Tisone G, Manzia TM. Pancreatic Adeno-MiNEN, a Rare Newly Defined Entity with Challenging Diagnosis and Treatment: A Case Report with Systematic Literature Review and Pooled Analysis. JCM 2022;11:5021. [DOI: 10.3390/jcm11175021] [Reference Citation Analysis]
6 Greenberg JA, Ivanov NA, Egan CE, Lee YJ, Zarnegar R, Fahey TJ 3rd, Finnerty BM, Min IM. Sex-Based Clinicopathologic and Survival Differences Among Patients with Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2022. [PMID: 35915373 DOI: 10.1007/s11605-022-05345-6] [Reference Citation Analysis]
7 Hackeng WM, Assi HA, Westerbeke FH, Brosens LA, Heaphy CM. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.05.007] [Reference Citation Analysis]
8 Quan L, Liu Y, Cui W, Wang X, Zhang W, Wang Z, Guo C, Lu C, Hu F, Chen X. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms. Lipids Health Dis 2022;21:58. [PMID: 35842659 DOI: 10.1186/s12944-022-01669-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ma ST, Wang DY, Liu YB, Tan HJ, Ge YY, Chi Y, Zhang BL. Prognostic factors of primary neuroendocrine breast cancer: A population-based study. Cancer Med 2022. [PMID: 35499193 DOI: 10.1002/cam4.4557] [Reference Citation Analysis]
10 Huang J, Xie X, Wu H, Zhang X, Zheng Y, Xie X, Wang Y, Xu M. Development and validation of a combined nomogram model based on deep learning contrast-enhanced ultrasound and clinical factors to predict preoperative aggressiveness in pancreatic neuroendocrine neoplasms. Eur Radiol 2022. [PMID: 35389050 DOI: 10.1007/s00330-022-08703-9] [Reference Citation Analysis]
11 Bian Y, Jiang H, Zheng J, Shao C, Lu J. Basic pancreatic lesions: Radiologic-pathologic correlation. Journal of Translational Internal Medicine 2022;10:18-27. [DOI: 10.2478/jtim-2022-0003] [Reference Citation Analysis]
12 Zheng-Pywell R, Lopez-Aguiar A, Fields RC, Vickers S, Yates C, Dudeja V, Chen H, Reddy S, Maithel SK, Rose JB. Are We Undertreating Black Patients with Nonfunctional Pancreatic Neuroendocrine Tumors? Critical Analysis of Current Surveillance Guidelines by Race. J Am Coll Surg 2022;234:599-606. [PMID: 35380181 DOI: 10.1097/XCS.0000000000000105] [Reference Citation Analysis]
13 Hou J, Long T, Yang Y, Chen D, Hu S, Azhdarinia A. The Potential Prognostic Value of Dual-Imaging PET Parameters Based on 18F-FDG and 18F-OC for Neuroendocrine Neoplasms. Molecular Imaging 2022;2022:1-9. [DOI: 10.1155/2022/6511179] [Reference Citation Analysis]
14 Siebenhüner AR, Langheinrich M, Friemel J, Schäfer N, Eshmuminov D, Lehmann K. Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor. Cancers (Basel) 2022;14:1478. [PMID: 35326628 DOI: 10.3390/cancers14061478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Shyr BS, Shyr BU, Chen SC, Shyr YM, Wang SE. Impact of tumor grade on pancreatic neuroendocrine tumors. Asian J Surg 2022:S1015-9584(22)00149-X. [PMID: 35246343 DOI: 10.1016/j.asjsur.2022.01.094] [Reference Citation Analysis]
16 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wang J, Liu J, He C, Sun T, Yan Y, Che G, Li X, Sun H, Ma H. Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987-2016. J Oncol 2021;2021:4302675. [PMID: 34976056 DOI: 10.1155/2021/4302675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hou J, Yang Y, Chen N, Chen D, Hu S. Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:771912. [PMID: 34901087 DOI: 10.3389/fmed.2021.771912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liao T, Su T, Huang L, Li B, Feng LH. Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms. Scand J Gastroenterol 2021;:1-6. [PMID: 34592854 DOI: 10.1080/00365521.2021.1984571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Sadowski SM, Pieterman CRC, Perrier ND, Triponez F, Valk GD. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature. Endocr Relat Cancer 2020;27:R145-61. [PMID: 32229700 DOI: 10.1530/ERC-19-0372] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
21 Aysal A, Agalar C, Egeli T, Unek T, Oztop I, Obuz F, Sagol O. Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis. Endocr Pathol 2021. [PMID: 34283399 DOI: 10.1007/s12022-021-09687-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Lu X, Yan S, Koral KA, Chen Z. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. Expert Rev Anticancer Ther 2021;21:917-26. [PMID: 34142932 DOI: 10.1080/14737140.2021.1944110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Cukier M, Vergara R, Mendez-Rios JD, Castillo O, Barrera I, Tello E, El Achtar O, Loo Y, Tapia H, Perez G, Peña M. Neuroendocrine tumors in Panama: A nationwide database analysis. Mol Clin Oncol 2021;15:157. [PMID: 34178328 DOI: 10.3892/mco.2021.2319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Xie S, Li L, Wang X, Li L. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Medicine (Baltimore) 2021;100:e24223. [PMID: 33466202 DOI: 10.1097/MD.0000000000024223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Chen J, Yang Y, Liu Y, Kan H. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation. World J Surg Oncol 2021;19:11. [PMID: 33436017 DOI: 10.1186/s12957-020-02115-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
27 Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, Custodio A, Benavent M, Goñi S, García-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, López C, Jiménez-Fonseca P, San Vicente BL, González-Borja I, Sevilla I, Hernández-Garcia I, Carmona-Bayonas A, Capdevila J, Pérez-Sanz J, García-Carbonero R, Pérez-Ricarte L, Llanos M, Vera R, De Jesús Acosta A. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Pancreatology 2021;21:215-23. [PMID: 33358592 DOI: 10.1016/j.pan.2020.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 12.5] [Reference Citation Analysis]
29 He R, Zhang W, Chen S, Liu Y, Yang W, Li J. Transcriptional Profiling Reveals the Regulatory Role of DNER in Promoting Pancreatic Neuroendocrine Neoplasms. Front Genet 2020;11:587402. [PMID: 33329729 DOI: 10.3389/fgene.2020.587402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22:685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Kim J, Hwang HK, Lee WJ, Kang CM. Minimally invasive vs open pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors. World J Gastrointest Oncol 2020; 12(10): 1133-1145 [PMID: 33133382 DOI: 10.4251/wjgo.v12.i10.1133] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Chen BB. Artificial intelligence in pancreatic disease. Artif Intell Med Imaging 2020; 1(1): 19-30 [DOI: 10.35711/aimi.v1.i1.19] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]